Novel Therapy Combining Regenerative Stimuli Immunomodulation to Preserve Beta Cell Function in New Onset Type 1 Diabetes.

Trial Profile

Novel Therapy Combining Regenerative Stimuli Immunomodulation to Preserve Beta Cell Function in New Onset Type 1 Diabetes.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 02 Jan 2013

At a glance

  • Drugs GAD65 vaccine (Diamyd) (Primary) ; Lansoprazole (Primary) ; Sitagliptin (Primary) ; Insulin
  • Indications Type 1 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 20 Mar 2012 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 30 Mar 2011 Actual end date (Mar 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top